ArticleDiscover oncology2026
Leveraging mitochondrial dynamics-related risk signatures to predict the prognosis and tumor microenvironment of lung adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) is a highly heterogeneous disease, bringing daunting challenges in prognosis prediction. Alterations in mitochondrial dynamics (MD) are crucial in tumor generation and progression. Therefore, this study is the first to build a prognostic model based on mitochondrial dynamics-related genes (MDRGs) to predict microenvironment and potential drugs for LUAD.
methodsLUAD transcriptomic data were sourced from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), respectively. First, differentially expressed genes (DEGs) were screened between normal and LUAD samples in the TCGA cohort. The intersection of DEGs and MDRGs yielded differentially expressed MDRGs (DE-MDRGs). Then, a prognostic model was constructed through univariate Cox regression, LASSO Cox regression, and multivariate Cox regression analysis. A nomogram was graphed using clinical factors and the MD-related risk score (MDRS). The predictive performance of the model and the nomogram was evaluated using ROC curves. Finally, analyses on tumor microenvironment (TME), mutation, and predicted in vitro drug response were undertaken.
resultsA prognostic model based on 8 MDRGs (SLC52A3, HMGA2, CPS1, GLS2, CYP27A1, CFTR, STAR, and DRP2) was established, demonstrating relatively accurate predictive ability. The low-MDRS group had higher levels of immune cell infiltration, such as aDCs, B cells, neutrophils, and tumor-infiltrating lymphocytes. We also discovered that the tumor mutation burden in the high-MDRS group was considerably higher than that in the low-MDRS group. Additionally, the low-MDRS group was more sensitive to AZD8055, ZM447439, ERK-6604, SB505124, Tozasertib, and BMS-754807, while the high-MDRS group was more sensitive to BI-2536 and Venetoclax.
conclusionThis work set up a prognostic model for LUAD based on 8 MDRGs, pinpointing promising biomarkers and targets for LUAD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.